James M. Frates - Oct 31, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Oct 31, 2023
Transactions value $
$0
Form type
4
Date filed
11/2/2023, 03:33 PM
Previous filing
Sep 5, 2024
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Gift $0 +11.1K $0.00 11.1K Oct 31, 2023 By Trust F1, F2
holding AMLX Common Stock 115K Oct 31, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 31, 2023, the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person served as trustee and sole annuitant, liquidated and returned 8,410 shares to the Reporting Person as an annuity payment, transferring the remaining 11,072 shares to the FRATES FAMILY 2013 IRREV TRUST for no consideration.
F2 Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.